RECRUITING · INTERVENTIONAL · TREATMENT study · Renal Cancer · Phase 2 · Enrollment 17 · Sponsor: University of Colorado, Denver
Official title: Neoadjuvant Pembrolizumab and Axitinib in Renal Cell Carcinoma With Associated Inferior Vena Cava Tumor Thrombus (NEOPAX)
Summary: The primary objective of this study is to evaluate whether the combination of Pembrolizumab and Axitinib given in the neoadjuvant setting can change the Inferior Vena Cava Tumor Thrombus burden. A decrease in the size of the tumor thrombus can potentially lead to decrease in surgical complications, improve patient related health outcomes, and improve long term outcomes such as progression free survival and overall survival.
Conditions: Renal Cancer, Kidney Cancer, Renal Cell Carcinoma, Inferior Vena Cava Thrombosis
Study type: INTERVENTIONAL
Primary purpose: TREATMENT
Phases: PHASE2
Enrollment: 17 (ESTIMATED)
Status: RECRUITING
Completion: 2029-11 (ESTIMATED)